AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01474200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isolated veno-venous ultrafiltration (AQ)
Description: Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
Study NCT01474200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Loop Diuretics (LD)
Description: IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial.
Study NCT01049646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
Study NCT01049646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
Study NCT03714919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Preoperative oral dextromethorphan 1 mg/kg
Study NCT03714919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Preoperative oral acetaminophen 15 mg/kg
Study NCT02138552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
Study NCT03714919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative intravenous dexmedetomidine 0.5 μg/kg
Study NCT03714919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intraoperative intravenous ketamine 0.5 mg/kg
Study NCT00100880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT00100880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perfusion-weighted magnetic resonance imaging
Description: Correlative studies
Study NCT00100880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Correlative studies
Study NCT00100880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00237393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
Study NCT00237393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
Study NCT03041428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraprotective ventilation
Description: Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
Study NCT04004585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Up For Your Health
Description: The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting.
Study NCT02108093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrograde autologous priming
Description: Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
Study NCT04085055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Solid pancreatic mass lesion biopsy
Description: The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
Study NCT04272385 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT03261492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
Study NCT03261492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Safety Attention Comparison
Description: The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
Study NCT03533309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided surgical cutting guide
Description: comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
Study NCT03533309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional alveolar ridge splitting
Description: comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
Study NCT01403857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain foods
Description: Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
Study NCT01403857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined grains
Description: Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
Study NCT01461447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Ankara
Description: Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
Study NCT00582010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: inhaled 80ppm for duration of surgery.
Study NCT00582010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrogen gas
Description: inhaled
Study NCT03417687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 129Xe MRI
Description: Evaluation of pulmonary function
Study NCT03417687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 133 Xe scintigraphy
Description: Evaluation of pulmonary function
Study NCT02879903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets.
Study NCT02879903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiological collect
Description: Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
Study NCT02879903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
Study NCT01652547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide sub-cutaneous formulation
Description: Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
Study NCT01652547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide lon acting release formulation
Description: At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
Study NCT02124772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
Study NCT04589143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
Study NCT03907943 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: carotid endarterectomy
Description: Surgical treatment of ICA stenosis.
Study NCT03006952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
Study NCT03006952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: losartan arm took 100mg losartan daily for 12 weeks.
Study NCT05536934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nω-hydroxy-nor-arginine
Study NCT02925780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months).
Study NCT02925780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microabrasion
Description: The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months).
Study NCT00819052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine XR
Description: Nevirapine XR
Study NCT00819052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine XR
Description: Nevirapine extended release
Study NCT00819052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine IR
Description: Nevirapine Immediate Release
Study NCT00531310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning, Busulfan and Fludarabine
Description: Busulfan and Fludarabine
Study NCT04678193 — intervention group
Intervention type: DRUG
Intervention: Coromec Registry with ECL-19
Description: Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
Study NCT02397980 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention
Description: * What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves
Study NCT04230902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microfragmented Adipose Tissue Transplant
Description: Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit
Study NCT04230902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: intra-articular knee injection of corticosteroid
Study NCT01450683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-\[4-(4-{\[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl\]methoxy}phenyl)piperazin-1-yl\]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
Study NCT02348255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electric Field Therapy
Description: Undergo NovoTTF-100A
Study NCT02348255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02348255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT02348255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01559389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
Study NCT03022097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol Fixed-Dose Combination
Description: Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
Study NCT03022097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
Study NCT03022097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
Study NCT03022097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
Study NCT02637531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
Study NCT00003167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene
Description: Given intravesically
Study NCT02636114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
Study NCT02637531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
Study NCT04589143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
Study NCT02522442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure
Study NCT02522442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto BiLevel
Description: Auto Bilevel positive airway pressure with Flex
Study NCT04170387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxometer
Description: Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
Study NCT04170387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxometer
Description: Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
Study NCT01756859 — intervention group
Intervention type: PROCEDURE
Intervention: MRI Scan
Study NCT00647114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V930
Description: V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
Study NCT00647114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V932
Description: V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
Study NCT03817073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa Oral Performance Instrument (IOPI)
Description: Using biofeedback to attain repetitions of 80% of baseline MIP.
Study NCT03217032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YUVA-GT-F801
Description: Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
Study NCT04625868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Patients will watch a preoperative educational video on proper opioid use and disposal.
Study NCT02680743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education of parents to pursue prompt hearing screening.
Description: Parents of patients will be counseled on the risks of hearing loss with a positive screen.
Study NCT00322946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-4995
Description: Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
Study NCT03381144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0334
Description: Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
Study NCT03381144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive GDC-0334-matching placebo.
Study NCT01641029 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention
Study NCT01048827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^
Study NCT00982267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU014813
Description: Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
Study NCT00621764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)
Description: ≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
Study NCT00621764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
Description: 0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)